Standard treatment of ROP, diode-laser photocoagulation inhibits VEGF production by destroying the avascularised, peripheral, ischemic retina, which produces various growth factors such as VEGF, transforming growth factor, beta3 TGF-β3), erythropoetine (EPO) [8], angiopoietin-like protein 4, ANGPTL4 [9] and others, but does not affect the level of VEGF, which has already been secreted into the vitreous body and subretinal area. The gene discussed is VEGFA; the disease is retinopathy of prematurity.